Industry news that matters to you.  Learn more

Archives for November 2011

GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011

FirstMark, the diagnostic division of GenWay Biotech, Inc., recently announced study results and the commercial launch of PREvent. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction (MI) for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent was launched, and the data from the phase I prospective study entitled, “Aggregate Risk Score Based on Markers of Inflammation, Immunity, and Thrombosis is an Independent Predictor of Adverse Cardiovascular Outcomes,” was presented by Danny J. Eapen, MD, at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida.

NIH to Support Clinical Utility Validation of New Molecular Diagnostic Tests

The National Institutes of Health announced yesterday that the National Cancer Institute will support applications to perform validation of the clinical usefulness of new molecular diagnostics for prognosis or prediction of the response to therapy for cancer.

OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies

OncoSec Medical Incorporated, which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, today announced it has entered into a collaborative research agreement with Serametrix Corporation to analyze subjects in three OncoSec Phase II clinical trials treating melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma with the goal of identifying biomarkers that may refine and enhance the selection of patients potentially responsive to these treatments. Terms of the final agreement have not been released.

GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development and Commercialization

GVK Biosciences, Asia’s leading drug discovery research and development organization, announced today a new partnership with the PROOF Centre of Excellence, focusing on biomarker development for heart, lung and kidney failure.

Novel Nanocrystals with Advanced Optical Properties Developed for Use as Luminescent Biomarkers

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.